Clinical trials: Diabetes Type 2
Type 2 Diabetes Mellitus
Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan
To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID).
- Trial name
- NCT01318135
- Testing
- Alogliptin and glimepiride, Alogliptin and metformin
- Volunteers
- 576 people
- Sponsor
- Takeda
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease, Type 2 Diabetes
- Trial name
- GLP1-SGLT2-CKM (NCT07465926)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor
- Volunteers
- 451,036 people
- Sponsor
- Chung Shan Medical University
Diabetes Mellitus, Type 2
Linagliptin Add-on to Insulin Background Therapy
To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control
- Trial name
- NCT02897349
- Testing
- linagliptin, background therapy
- Where
- 25 sites in China
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
- Trial name
- NCT00885378
- Testing
- Saxagliptin plus metformin IR
- Where
- 41 sites in United States, Germany and 2 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 2 diabetes (T2D).
- Trial name
- NCT03952143
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 41 sites in Argentina, China and 1 more
- Volunteers
- 628 people
- Sponsor
- Eli Lilly and Company
Frailty, Weight, Body
Effect of Behavioral Lifestyle Intervention on Frailty in Older Adults With Diabetes
The study team want to see if changes in lifestyle and behaviors and self-monitoring of diet and physical activity in older adults who have type 2 Diabetes (T2D) may help to prevent or reduce frailty.
- Conditions
- Frailty, Weight, Body, Type 2 Diabetes
- Trial name
- NCT04440449
- Testing
- Lifestyle App, Look AHEAD behavior lifestyle intervention, Abbreviated Look AHEAD behavior lifestyle intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2, Medication Adherence
Reinforcement Learning in Diabetes Mellitus Trial
Reinforcement learning is an advanced analytic method that discovers each individual's pattern of responsiveness by observing their actions and then implements a personalized strategy to optimize individuals' behaviors using…
- Trial name
- REINFORCE (NCT04473326)
- Testing
- Reinforcement Learning
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus
Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid
The hypothesis for this study is that pancreas lipid will be more closely associated with first-phase beta-cell response in African-Americans than in European-Americans, both at baseline and in response to treatment.
- Trial name
- NCT03430310
- Testing
- Low Glycemic Diet, Control Diet
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes…
- Trial name
- NCT00601250
- Testing
- linagliptin
- Where
- 82 sites in United States, Czechia and 8 more
- Volunteers
- 701 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Healthy
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
The objective of this proposal is to provide quantitative dose-response data for effects of GLP-1 on myocardial glucose uptake in healthy control subjects and obese type 2 diabetic subjects, in support of the design of later…
- Trial name
- NCT01607450
- Testing
- GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Indiana University
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
This trial is designed to evaluate, in adult participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on sub-maximal metformin mono-therapy (1000 mg/day), the effect of up-titration of metformin plus the…
- Trial name
- NCT02791490
- Testing
- Sitagliptin, Metformin IR
- Volunteers
- 458 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
- Trial name
- NCT00135330
- Testing
- exenatide, rosiglitazone
- Where
- 19 sites in United States
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study on the Effect of 2 Pen Devices on HbA1c
The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional…
- Trial name
- NCT00985712
- Testing
- Insulin Lispro, Huminsulin Regular, HumaPen Memoir
- Where
- 29 sites in Germany
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Hypertension
Motivational Interviewing (MI) Intervention to Improve Adherence
The purpose of this study is to examine the effectiveness of a telephone motivational interviewing intervention by pharmacy students in enhancing adherence to angiotensin converting enzyme inhibitors (ACEI)/ angiotensin receptor…
- Trial name
- MI (NCT03985098)
- Testing
- Motivational interviewing intervention arm
- Where
- United States
- Volunteers
- 727 people
- Sponsor
- University of Houston
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes.
- Trial name
- AWARD-1 (NCT01064687)
- Testing
- LY2189265, Exenatide, Metformin
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 978 people
- Sponsor
- Eli Lilly and Company
Healthy, Type 2 Diabetes Mellitus (T2DM)
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
The main purposes of this study are to determine: The safety of tirzepatide and any side effects that might be associated with it. How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT02759107
- Testing
- Tirzepatide, Dulaglutide
- Where
- 2 sites in United States, Singapore
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
The purpose of this study is to examine the effect CGM (continuous glucose monitoring) has on subjects with type 2 diabetes. It is anticipated that patients using the device will obtain tighter control of their blood sugars…
- Trial name
- DexlonT2 (NCT01341067)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rocky Mountain Diabetes and Osteoporosis Center
Type 2 Diabetes, Oxidative Stress
Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes
Oxidative stress has been implicated in the development and complications of diabetes. Hyperglycemia and insulin resistance or insufficiency in diabetes can cause oxidative stress by excessive reactive oxygen species and can…
- Trial name
- NCT00845130
- Testing
- ascorbic acid (Vitamin C)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- In-Young Choi, Ph.D.
Type 1 Diabetes Mellitus
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes…
- Trial name
- EDITION JUNIOR (NCT02735044)
- Testing
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Where
- 107 sites in United States, Argentina and 22 more
- Volunteers
- 463 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.